GFRAL and neoplasm: In a variety of human and mouse GDF‐15 secreting tumour models, tumour implantation caused an increase in circulating GDF‐15 levels, resulting in a decline in body weight (fat and skeletal muscle lean mass), food intake, skeletal muscle strength (force generation), physical activity (home cage locomotion and voluntary wheel running), exercise tolerance (treadmill running) and survival in animals, which were all reversed by GDF‐15/GFRAL neutralizing antibodies, including ponsegromab.8, 17, 18, 19